{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:18:29Z","timestamp":1760955509163},"reference-count":162,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tcmonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.tcm.2014.10.017","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T19:04:30Z","timestamp":1414695870000},"page":"315-336","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?"],"prefix":"10.1016","volume":"25","author":[{"given":"Mikhail S.","family":"Dzeshka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tcm.2014.10.017_bib1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"ESC Committee for Practice Guidelines\u2014CPG; Document reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.tcm.2014.10.017_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","author":"January","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1160\/TH14-03-0231","article-title":"Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study","volume":"111","author":"Lowres","year":"2014","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH13-02-0165","article-title":"Screening to identify unknown atrial fibrillation. A systematic review","volume":"110","author":"Lowres","year":"2013","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH14-03-0228","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel","volume":"111","author":"Husted","year":"2014","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.tcm.2014.10.017_bib9","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation Cohort Study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a \u2018real world\u2019 nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.tcm.2014.10.017_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1538-7836.2010.04085.x","article-title":"A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice","volume":"9","author":"Van Staa","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.tcm.2014.10.017_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib14","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0\u20131: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.tcm.2014.10.017_bib16","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?","volume":"34","author":"Lip","year":"2013","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.tcm.2014.10.017_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9526","key":"10.1016\/j.tcm.2014.10.017_bib18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2014.10.017_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","article-title":"Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation","volume":"37","author":"Birman-Deych","year":"2006","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib20","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-11-0768","article-title":"Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims\u2014data of 183,448 patients","volume":"107","author":"Wilke","year":"2012","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1160\/TH13-12-1007","article-title":"Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry","volume":"111","author":"Le Heuzey","year":"2014","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib23","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib24","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAME-TT2R2 score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation","volume":"146","author":"Lip","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH13-09-0730","article-title":"Targeting factor Xa and thrombin: impact on coagulation and beyond","volume":"111","author":"Esmon","year":"2014","journal-title":"Thromb Haemost"},{"issue":"28","key":"10.1016\/j.tcm.2014.10.017_bib29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/eurheartj\/ehu181","article-title":"Edoxaban: a focused review of its clinical pharmacology","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.tcm.2014.10.017_bib30","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.tcm.2014.10.017_bib31","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tcm.2014.10.017_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tcm.2014.10.017_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib34","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.tcm.2014.10.017_bib35","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","article-title":"External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?","volume":"9","author":"Beyer-Westendorf","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1538-7836.2008.02836.x","article-title":"Double-blindness protects scientific validity","volume":"6","author":"Furberg","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jth.12086","article-title":"Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?","volume":"11","author":"Rodriguez","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib39","first-page":"51","article-title":"Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism","volume":"4","author":"Kneeland","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.tcm.2014.10.017_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/pds.1556","article-title":"Risk factors for nonadherence to warfarin: results from the IN-RANGE study","volume":"17","author":"Platt","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10928-007-9058-0","article-title":"Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics","volume":"34","author":"Comt\u00e9","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"10.1016\/j.tcm.2014.10.017_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.mayocp.2014.01.030","article-title":"Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients","volume":"89","author":"Chatterjee","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tcm.2014.10.017_bib43","article-title":"Best practice for atrial fibrillation patient education","author":"Barker","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.tcm.2014.10.017_bib44","first-page":"6","article-title":"Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation","author":"Clarkesmith","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.tcm.2014.10.017_bib45","doi-asserted-by":"crossref","first-page":"e74037","DOI":"10.1371\/journal.pone.0074037","article-title":"Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial","volume":"8","author":"Clarkesmith","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11239-012-0857-9","article-title":"Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?","volume":"35","author":"Dale","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"10.1016\/j.tcm.2014.10.017_bib47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.tcm.2014.10.017_bib48","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.tcm.2014.10.017_bib49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulants for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"9921","key":"10.1016\/j.tcm.2014.10.017_bib50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib51","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.tcm.2014.10.017_bib52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Lalibert\u00e9","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-013-1029-2","article-title":"A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban","volume":"38","author":"Kreutz","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.tcm.2014.10.017_bib54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tcm.2014.10.017_bib55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib56","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib57","doi-asserted-by":"crossref","first-page":"e99276","DOI":"10.1371\/journal.pone.0099276","article-title":"Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria","volume":"9","author":"Clemens","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib58","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib59","doi-asserted-by":"crossref","first-page":"g4670","DOI":"10.1136\/bmj.g4670","article-title":"Dabigatran: how the drug company withheld important analyses","volume":"349","author":"Cohen","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.tcm.2014.10.017_bib60","doi-asserted-by":"crossref","first-page":"g4681","DOI":"10.1136\/bmj.g4681","article-title":"The trouble with dabigatran","volume":"349","author":"Charlton","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.tcm.2014.10.017_bib61","doi-asserted-by":"crossref","first-page":"g4517","DOI":"10.1136\/bmj.g4517","article-title":"Dabigatran, bleeding, and the regulators","volume":"349","author":"Moore","year":"2014","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2014.10.017_bib63","unstructured":"Boehringer Ingelheim. Benefits and safety of Pradaxa\u00ae (dabigatran etexilate mesylate) repeatedly confirmed. British Medical Journal publishes biased article regarding PRADAXA. Press Release. Available from: http:\/\/us.boehringer-ingelheim.com\/news_events\/press_releases\/press_release_archive\/2014\/07-23-14-benefits-safety-pradaxa-dabigatran-etexilate-mesylate-repeatedly-confirmed.html; 2014 [08.08.2014]."},{"issue":"21","key":"10.1016\/j.tcm.2014.10.017_bib64","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib65","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"issue":"28","key":"10.1016\/j.tcm.2014.10.017_bib66","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.tcm.2014.10.017_bib67","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Ann Intern Med"},{"issue":"9855","key":"10.1016\/j.tcm.2014.10.017_bib68","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.tcm.2014.10.017_bib69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib70","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.tcm.2014.10.017_bib71","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/eurjhf\/hft111","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial","volume":"15","author":"Ferreira","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib72","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.112.000143","article-title":"Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"6","author":"McMurray","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10.1016\/j.tcm.2014.10.017_bib73","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib74","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib76","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"issue":"9745","key":"10.1016\/j.tcm.2014.10.017_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib79","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","article-title":"Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial","volume":"3","author":"Piccini","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib80","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","volume":"127","author":"Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib81","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ahj.2013.05.016","article-title":"Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial","volume":"166","author":"Garcia","year":"2013","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40119-013-0019-y","article-title":"Anticoagulation in patients aged \u226575 years with atrial fibrillation: role of novel oral anticoagulants","volume":"2","author":"Ng","year":"2013","journal-title":"Cardiol Ther"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib83","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.tcm.2014.10.017_bib85","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.tcm.2014.10.017_bib86","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib87","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH13-04-0351","article-title":"Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation","volume":"110","author":"Bernard","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib88","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.tcm.2014.10.017_bib89","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib90","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1160\/TH10-05-0332","article-title":"Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes","volume":"104","author":"Depta","year":"2010","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.tcm.2014.10.017_bib91","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1538-7836.2004.00899.x","article-title":"Atrial fibrillation and thrombosis: immunohistochemical differences between insitu and embolized thrombi","volume":"2","author":"Wysokinski","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.tcm.2014.10.017_bib92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib93","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/jama.2013.278787","article-title":"Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents","volume":"310","author":"Hawn","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.tcm.2014.10.017_bib94","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tcm.2014.10.017_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"9683","key":"10.1016\/j.tcm.2014.10.017_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib97","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.tcm.2014.10.017_bib98","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib99","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.tcm.2014.10.017_bib100","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"Eur Heart J"},{"issue":"2 Suppl","key":"10.1016\/j.tcm.2014.10.017_bib101","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"American College of Chest Physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"28","key":"10.1016\/j.tcm.2014.10.017_bib102","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","article-title":"Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry","volume":"35","author":"Beyer-Westendorf","year":"2014","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib103","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.tcm.2014.10.017_bib104","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"},{"issue":"10, Suppl","key":"10.1016\/j.tcm.2014.10.017_bib105","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/j.cjca.2013.07.375","article-title":"Use of apixaban and warfarin in patients undergoing invasive procedures: insights from Aristotle","volume":"29","author":"Lopes","year":"2013","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib106","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1160\/TH13-05-0431","article-title":"Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?","volume":"111","author":"Dickneite","year":"2014","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib107","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH12-05-0319","article-title":"New direct oral anticoagulants\u2014current therapeutic options and treatment recommendations for bleeding complications","volume":"108","author":"Miesbach","year":"2012","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.tcm.2014.10.017_bib108","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib109","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH12-08-0573","article-title":"Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease","volume":"109","author":"Khadzhynov","year":"2013","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.tcm.2014.10.017_bib111","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip","year":"2010","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib112","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1161\/STROKEAHA.109.576967","article-title":"Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants","volume":"41","author":"Strazzullo","year":"2010","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.tcm.2014.10.017_bib113","doi-asserted-by":"crossref","first-page":"640.e9","DOI":"10.1016\/j.amjmed.2012.11.024","article-title":"Body mass index and adverse events in patients with incident atrial fibrillation","volume":"126","author":"Overvad","year":"2013","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib114","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1378\/chest.13-1740","article-title":"The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer and Health study","volume":"145","author":"Albertsen","year":"2014","journal-title":"Chest"},{"issue":"15","key":"10.1016\/j.tcm.2014.10.017_bib115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/heartjnl-2013-304036","article-title":"Alcohol intake and prognosis of atrial fibrillation","volume":"99","author":"Overvad","year":"2013","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib116","doi-asserted-by":"crossref","DOI":"10.1160\/TH14-03-0272","article-title":"Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients","volume":"112","author":"Schaefer","year":"2014","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.tcm.2014.10.017_bib117","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.tcm.2014.10.017_bib118","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Par\u00e9","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2014.10.017_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2014.08.038","article-title":"Cardioembolic stroke in a patient taking dabigatran etexilate: the first case report of clinical and pharmacologic resistance","author":"Sargento-Freitas","year":"2014","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.tcm.2014.10.017_bib120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1160\/TH13-08-0667","article-title":"Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?","volume":"111","author":"Paciaroni","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cjca.2011.10.002","article-title":"Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study","volume":"28","author":"Yung","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.tcm.2014.10.017_bib122","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.tcm.2014.10.017_bib123","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/WNL.0000000000000245","article-title":"Italian Federation of Anticoagulation Clinics (FCSA). Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study","volume":"82","author":"Poli","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.tcm.2014.10.017_bib124","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1161\/01.STR.0000078311.18928.16","article-title":"Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis","volume":"34","author":"Eckman","year":"2003","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/01.wnl.0000194267.09060.77","article-title":"Antiplatelet use after intracerebral hemorrhage","volume":"66","author":"Viswanathan","year":"2006","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib126","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.56.6.773","article-title":"Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage","volume":"56","author":"Bailey","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.tcm.2014.10.017_bib127","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"41","author":"Morgenstern","year":"2010","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.tcm.2014.10.017_bib128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/ijs.12309","article-title":"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage","volume":"9","author":"Steiner","year":"2014","journal-title":"Int J Stroke."},{"key":"10.1016\/j.tcm.2014.10.017_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1476-511X-13-47","article-title":"Apolipoprotein E gene polymorphism and the risk of intracerebral hemorrhage: a meta-analysis of epidemiologic studies","volume":"13","author":"Zhang","year":"2014","journal-title":"Lipids Health Dis"},{"issue":"8","key":"10.1016\/j.tcm.2014.10.017_bib130","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/STROKEAHA.114.005151","article-title":"Incidence of symptomatic hemorrhage in patients with lobar microbleeds","volume":"45","author":"van Etten","year":"2014","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib131","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-152-2-201001190-00009","article-title":"International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding","volume":"152","author":"Barkun","year":"2010","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib132","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2014.10.017_bib133","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tcm.2014.10.017_bib134","first-page":"1","article-title":"Anticoagulant-related gastrointestinal bleeding\u2014could this facilitate early detection of benign or malignant gastrointestinal lesions?","author":"Clemens","year":"2014","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1160\/TH12-06-0438","article-title":"Indirect comparison studies\u2014are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation","volume":"108","author":"Skj\u00f8th","year":"2012","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib136","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban, and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tcm.2014.10.017_bib137","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib138","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1160\/TH14-02-0118","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis","volume":"111","author":"Skj\u00f8th","year":"2014","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.tcm.2014.10.017_bib139","doi-asserted-by":"crossref","first-page":"e100478","DOI":"10.1371\/journal.pone.0100478","article-title":"Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons","volume":"9","author":"Verdecchia","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.tcm.2014.10.017_bib140","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ahj.2013.12.024","volume":"167","author":"Ezekowitz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.tcm.2014.10.017_bib141","unstructured":"John H. Stroger Hospital. Anticoagulation with rivaroxaban in cardioversion\u2014The ARC study. NLM Identifier: NCT01747746. Available from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01747746; 2012 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib142","unstructured":"Pfizer. Study of the blood thinner, apixaban, for patients who have an abnormal heart rhythm (atrial fibrillation) and expected to have treatment to put them back into a normal heart rhythm (Cardioversion) (EMANATE). NLM Identifier: NCT02100228. Available from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02100228; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib143","unstructured":"Daiichi Sankyo Inc. Edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF). NLM Identifier: NCT02072434. Available from http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02072434; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib144","unstructured":"Skanes A. DAPPAR A.F. Dabigatran for peri procedural anticoagulation during radiofrequency ablation of atrial fibrillation (DAPPARAF). NLM Identifier: NCT01468155. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01468155; 2011 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib145","unstructured":"Nickenig G. Prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation (ODIn-AF). NLM Identifier: NCT02067182. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02067182; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib146","unstructured":"Vanderbilt University. Use of dabigatran etexilate to prevent stroke and thromboembolism. NLM Identifier: NCT01976507. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01976507; 2013 [accessed 20.08.14]."},{"issue":"2","key":"10.1016\/j.tcm.2014.10.017_bib147","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10840-014-9924-9","article-title":"Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation","volume":"41","author":"Naccarelli","year":"2014","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.tcm.2014.10.017_bib148","unstructured":"University of Ottawa Heart Institute. Optimal Anticoagulation for higher risk patients post-catheter ablation for atrial fibrillation trial (OCEAN). NLM Identifier: NCT02168829. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02168829; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib149","unstructured":"Bayer. Exploring the efficacy of once daily oral rivaroxaban for treatment of thrombus in left atrial\/left atrial appendage in subjects with nonvalvular atrial fibrillation or atrial flutter (X-TRA). NLM Identifier: NCT01839357. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01839357; 2013 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib150","unstructured":"Boehringer Ingelheim. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI). NLM Identifier: NCT02164864. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02164864; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib151","unstructured":"Janssen Scientific Affairs, LLC. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). NLM Identifier: NCT01830543. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01830543; 2013 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib152","unstructured":"Fujita Health University. Registry for estimation of warfarin and rivaroxaban in atrial fibrillation patients with coronary stent implantation (REWRAPS). NLM Identifier: NCT02024230. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02024230; 2013 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib153","unstructured":"Japan Cardiovascular Research Foundation. RELAXED: recurrent embolism lessened by rivaroxaban for acute ischemic stroke. NLM Identifier: NCT02129920. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02129920; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib154","unstructured":"Asan Medical Center. Rivaroxaban versus warfarin in acute ischemic stroke with atrial fibrillation (TripleAXEL). NLM Identifier: NCT02042534. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02042534; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib155","unstructured":"Boehringer Ingelheim. Pradaxa study in non-valvular atrial fibrillation patients with severely impaired renal function. NLM Identifier: NCT01896297. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01896297; 2013 [accessed 20.08.14]."},{"issue":"13","key":"10.1016\/j.tcm.2014.10.017_bib156","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.tcm.2014.10.017_bib157","unstructured":"Hospital Ana Nery. Dabigatran versus warfarin after mitral and\/or aortic bioprosthesis replacement and atrial fibrillation postoperatively (DAWA). NLM Identifier: NCT01868243. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01868243; 2013 [accessed 20.08.14]."},{"issue":"3","key":"10.1016\/j.tcm.2014.10.017_bib158","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10840-014-9910-2","article-title":"Newer clinically available antithrombotics and their antidotes","volume":"40","author":"L\u00e9vy","year":"2014","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.tcm.2014.10.017_bib159","unstructured":"Boehringer Ingelheim. Reversal of dabigatran anticoagulant effect with idarucizumab. NLM Identifier: NCT02104947. Available from: http:\/\/clinicaltrials.gov\/show\/NCT02104947; 2014 [accessed 20.08.14]."},{"issue":"4","key":"10.1016\/j.tcm.2014.10.017_bib160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2014.10.017_bib161","unstructured":"Portola Pharmaceuticals. A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban. NLM Identifier: NCT02220725. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02220725; 2014 [accessed 20.08.14]."},{"key":"10.1016\/j.tcm.2014.10.017_bib162","unstructured":"Portola Pharmaceuticals. A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban. NLM Identifier: NCT02207725. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02207725; 2014 [accessed 20.08.14]."}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173814001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173814001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T03:51:29Z","timestamp":1538106689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173814001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":162,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1050173814001959"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2014.10.017","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2014.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}